Research and Markets: Leptin Signaling Pathway in Oncology Drug Pipeline Update 2014

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/wcg25d/leptin_signaling) has announced the addition of the "Leptin Signaling Pathway in Oncology Drug Pipeline Update 2014" report to their offering.

The binding of Leptin to its receptor, LEPR induces various signaling modules such as JAK/STAT, RAS/RAF/MAPK, IRS/PI-3K and AMPK/ACC.

There are today 261 companies plus partners developing 374 Leptin pathway targeting drugs in 1339 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 179 drugs.

Leptin Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 185 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 182 out of the 184 studied drug targets so far have been recorded with somatic mutations.

The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 41 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Drug Pipeline Update at a Glance

Investigators

  • Includes more than 261 principal companies plus their collaborators. There is direct access from inside the application to web

Drug name & Synonyms

  • Lists commercial, generic and code names for drugs.

Developmental stage

  • This Drug Pipeline Update contains 374 Leptin pathway targeting drugs in development, which have a total of 1339 developmental projects in cancer. In addition there are suspended and ceased drugs.

Indications

  • Included Leptin pathway targeting drugs are also in development for 190 other indications, where of 118 are different cancer indications.

Pipeline Breakdown According to Number of Drugs

  • Marketed # 33
  • Registered # 1
  • Pre-registration # 5
  • Phase III # 44
  • Phase II # 134
  • Phase I # 159
  • Preclinical # 184
  • No Data # 4
  • Suspended # 2
  • Ceased # 179

For more information visit http://www.researchandmarkets.com/research/wcg25d/leptin_signaling

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology